Latest News & Updates

Breaking News

7 hours ago
Vaibhavi M.

Medicus Completes Phase 2 Enrolment For D-MNA Microneedle Therapy In Basal Cell Carcinoma

Thermo Fisher Launches Next-Generation Gibco Media For Scalable E. coli Plasmid DNA Production;Enhance Yield, Consistency, And Scalability In Microbial Bioprocessing

Vaibhavi M.

Hikma Confirms Leadership Changes As Former CEO Returns And CFO Joins Board

Vaibhavi M.

FDA Approves AstraZeneca’s Enhertu Plus Pertuzumab As First-Line Treatment For HER2-Positive Metastatic Breast Cancer

Vaibhavi M.

Adaptive Biotechnologies Signs Two Non-Exclusive Research And Data Agreements With Pfizer Worth Up To $890M To Advance Autoimmune And Drug Discovery Programs

Simantini Singh Deo

Other trending news you may like to read

Medicus Completes Phase 2 Enrolment For D-MNA Microneedle Therapy In Basal Cell Carcinoma

Medicus Completes Phase 2 D-MNA Study Enrolment

Vaibhavi M.

Thermo Fisher Launches Next-Generation Gibco Media For Scalable E. coli Plasmid DNA Production;Enhance Yield, Consistency, And Scalability In Microbial Bioprocessing

Thermo Fisher launches Gibco Bacto CD Supreme media to streamline E. coli-based plasmid DNA and recombinant protein manufacturing for gene and mRNA therapies.

Vaibhavi M.

Hikma Confirms Leadership Changes As Former CEO Returns And CFO Joins Board

Hikma names Said Darwazah as CEO after Riad Mishlawi steps down, reaffirming its 2025 financial guidance.

Vaibhavi M.

FDA Approves AstraZeneca’s Enhertu Plus Pertuzumab As First-Line Treatment For HER2-Positive Metastatic Breast Cancer

FDA approves Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer, showing significant progression-free survival benefits.

Vaibhavi M.